Palantir’s NHS Data Platform Reportedly Expanded to Include GP Records

The Financial Times reported that general practitioner (GP) data has been added to Palantir Technologies’ data platform for the UK’s National Health Service (NHS), drawing attention to the scope of the health data now flowing through the system. The report characterised the addition as having taken place with limited public fanfare, raising questions about transparency around how patient information from primary care is integrated into the platform.

Palantir, a US-headquartered software company best known for data analytics work with government and defence customers, has been contracted to underpin the NHS Federated Data Platform, a centralised system intended to help health authorities combine and analyse operational data. The company’s commercial reach extends well beyond its defence and intelligence roots, and its work with the NHS has been one of its most prominent public-sector engagements in Europe.

The FT report noted that GP records — held by family doctors and covering a broad cross-section of the UK population — are now part of the data available on the platform. Patient data programmes in the UK health service have historically attracted scrutiny from privacy campaigners and medical professionals, and the pace and visibility of data onboarding decisions have been recurring points of debate.

For Palantir, the NHS engagement sits alongside a growing portfolio of government and commercial contracts that has driven significant revenue growth in recent years. The company trades as a large-cap software firm, with a market capitalisation of roughly $439.7 billion, and its shares closed recently at $170.50, down 0.07% from the prior close of $170.62.

As ever with coverage of data-platform expansions, the key questions centre on governance: which datasets are included, under what legal basis, and how access is controlled. Neither the report of the data addition itself nor the ongoing platform rollout changes Palantir’s financial disclosures, but public and political reaction to NHS data handling could shape the broader reception of the company’s public-sector work in the UK.

What to watch

• Any public statement from NHS England or Palantir clarifying the scope of GP data integration and consent arrangements.
• Responses from UK parliamentary committees or data-protection regulators regarding the Federated Data Platform.
• Palantir’s next quarterly earnings report, including commentary on government and healthcare segment revenue.

Source: original release via the Financial Times. For ongoing coverage, see Palantir Technologies (PLTR) on DefencePressWire.